Filter posts

Phase III Assets in High Demand - Results from the Business Forum Meeting Activity

At the BIO International Convention in Boston today, we released our results from the Business Forum …

Recent Developments in Patentability: Prometheus and Myriad

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at …

Only a Few Public Biotechs are Profitable, but There are More of Them Today

Of the 294 biotechs trading on public exchanges today, 248 (84%) focus on drug development. …

Indices, IPOs, and New Drug Approvals - Update April 3rd 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its …

Dealing with Rejection, the Regulatory Kind

The ubiquitous CRL in biotech has made its way into the news headlines again. But …

BIO Europe Spring 2012 - Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public …

Does Biotech History Repeat?

According to Mark Twain, “History does not repeat itself, but it does rhyme”. Little did he …

Update: Indices, IPOs, and New Drug Approvals

Here is a look at year to date (YTD) numbers through the end of February …

Oncology Clinical Trials - Secrets of Success

At last year’s BIO CEO & Investor Conference, BIO and BioMedTracker presented data showing that …

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at …